Two-channel Intravenous Patient-controlled Analgesia (IV-PCA) After Total Laparoscopic Hysterectomy (TLH)
Primary Purpose
Total Laparoscopic Hysterectomy, Patient-controlled Analgesia
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
convetional PCA method unsing only 1-channel
utilizing 2-channel
Sponsored by
About this trial
This is an interventional other trial for Total Laparoscopic Hysterectomy
Eligibility Criteria
Inclusion Criteria:
- patient who was scheduled to undergo elective TLH under general anesthesia, was a female aged 19-75 years, and had an American Society of Anesthesiologists physical status I-II
Exclusion Criteria:
- body mass index > 30.0 kg/m2, known hypersensitivity to the drugs used in this study, significant liver or renal dysfunction, or a history of drug abuse or dependence, recent major procedure or surgery, or preoperative analgesic use
Sites / Locations
- Department of Anaesthesiology and Pain Medicine, Korea University Guro Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
1-channel PCA
2-channel PCA
Arm Description
Ch-1: fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline) Ch-2: 100ml normal saline only (for blinding)
Ch-1: fentanyl 16 µg/kg (total volume 100 ml with normal saline) Ch-2: ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
Outcomes
Primary Outcome Measures
Korean version of the Quality of Recovery-40 questionnaire (QoR-40K) score
Patient recovery measured by QoR-40K score (maximum score 200)
Secondary Outcome Measures
Pain level was evaluated according to a numeric rating scale
(NRS; 0-100; no pain [0] to worst pain imaginable [100])
Cumulative consumption of PCA over 48 hours
The patient's overall satisfaction score
(0-10; 0 = un-satisfied to 10 = full-satisfied)
Occurrence of adverse effects
nausea and vomiting, dry mouth, dizziness, urinary retention, headache, sedation, itchiness, shivering, respiratory depression, confusion, hypotension, and bradycardia
Full Information
NCT ID
NCT04082039
First Posted
September 4, 2019
Last Updated
February 16, 2021
Sponsor
Korea University Guro Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04082039
Brief Title
Two-channel Intravenous Patient-controlled Analgesia (IV-PCA) After Total Laparoscopic Hysterectomy (TLH)
Official Title
The Efficacy of New Design Dual Channel Elastomeric Pump for Intravenous Patient-controlled Analgesia After Total Laparoscopic Hysterectomy: a Randomized, Double-blind, Prospective Study
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
September 3, 2019 (Actual)
Primary Completion Date
August 10, 2020 (Actual)
Study Completion Date
October 30, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Korea University Guro Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to compare the dual channel intravenous patient-controlled analgesia (IV-PCA) with single channel elastomeric pump (only one channel of dual channel pump is used for blinding and the other channel is filled with same volume of saline) in patients undergoing total laparoscopic hysterectomy, in terms of quality of recovery, efficacy of postoperative pain, drug consumption, adverse event, and patient subjective satisfaction.
Detailed Description
The Bellomic® M silicone balloon infuser, dual continuous petite type (cebika, Uiwang-si, Gyeonggi-do, Republic of Korea) is a newly designed IV-PCA device that is a 2-channel infusion elastomeric pump with two balloon chambers.
Conventional elastomeric IV-PCA devices were administered with a mixture of drugs in one chamber; when severe opioid related side effects occur, the IV-PCA administration is suspended by clipping, in this situation, not only the analgesic effect of opioid but also the effect of adjuvants could not be applied.
On the other hand, this newly designed device can be controlled as needed by administering adjuvant analgesics or antiemetic agents through another adjustable chamber. It will be expected that facilitate the pain management and increased the patient satisfaction and recovery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Total Laparoscopic Hysterectomy, Patient-controlled Analgesia
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
90 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1-channel PCA
Arm Type
Active Comparator
Arm Description
Ch-1: fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline) Ch-2: 100ml normal saline only (for blinding)
Arm Title
2-channel PCA
Arm Type
Experimental
Arm Description
Ch-1: fentanyl 16 µg/kg (total volume 100 ml with normal saline) Ch-2: ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
Intervention Type
Other
Intervention Name(s)
convetional PCA method unsing only 1-channel
Intervention Description
Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)
Intervention Type
Other
Intervention Name(s)
utilizing 2-channel
Intervention Description
Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
Primary Outcome Measure Information:
Title
Korean version of the Quality of Recovery-40 questionnaire (QoR-40K) score
Description
Patient recovery measured by QoR-40K score (maximum score 200)
Time Frame
At postoperative 24 hour
Secondary Outcome Measure Information:
Title
Pain level was evaluated according to a numeric rating scale
Description
(NRS; 0-100; no pain [0] to worst pain imaginable [100])
Time Frame
At 6, 12, 24, 36, 48 hours after surgery
Title
Cumulative consumption of PCA over 48 hours
Time Frame
At postoperative 48 hour
Title
The patient's overall satisfaction score
Description
(0-10; 0 = un-satisfied to 10 = full-satisfied)
Time Frame
At postoperative 48 hour
Title
Occurrence of adverse effects
Description
nausea and vomiting, dry mouth, dizziness, urinary retention, headache, sedation, itchiness, shivering, respiratory depression, confusion, hypotension, and bradycardia
Time Frame
Participants will be followed for their entire hospital stay, an expected average of 3-4 days
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patient who was scheduled to undergo elective TLH under general anesthesia, was a female aged 19-75 years, and had an American Society of Anesthesiologists physical status I-II
Exclusion Criteria:
body mass index > 30.0 kg/m2, known hypersensitivity to the drugs used in this study, significant liver or renal dysfunction, or a history of drug abuse or dependence, recent major procedure or surgery, or preoperative analgesic use
Facility Information:
Facility Name
Department of Anaesthesiology and Pain Medicine, Korea University Guro Hospital
City
Seoul
ZIP/Postal Code
08308
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
In order to protect patient priavacy and personal information, we will limit the provision of individual participant data
Citations:
PubMed Identifier
36224646
Citation
Oh SK, Kim H, Kim YS, Lee CH, Oh JS, Kwon DH. The effect of newly designed dual-channel elastomeric pump for intravenous patient-controlled analgesia after total laparoscopic hysterectomy: a randomized, double-blind, prospective study. Perioper Med (Lond). 2022 Oct 12;11(1):52. doi: 10.1186/s13741-022-00282-z.
Results Reference
derived
Learn more about this trial
Two-channel Intravenous Patient-controlled Analgesia (IV-PCA) After Total Laparoscopic Hysterectomy (TLH)
We'll reach out to this number within 24 hrs